Chengdu Meijiesaier Biotechnology

Chengdu Meijiesaier Biotechnology, also known as MedGenCell, is a high-tech enterprise established in 2015, focusing on cutting-edge precision cell therapy research and development. The company's primary business involves developing treatments for hematological and solid tumors using gene-editing technologies like CRISPR.

A significant milestone for the company was the development of what it calls "the world's first GMP-grade gene-edited T-cell product." In collaboration with West China Hospital of Sichuan University, MedGenCell completed the world's first human clinical trial of this nature. This achievement was noted in the journal 'Nature' and the full Phase I clinical results were published in 'Nature Medicine' in 2020. The company's pipeline includes PD-1 knockout engineered T-cells for treating conditions like non-small cell lung cancer.

The company operates its own GMP-compliant cell engineering and quality control rooms. Its technology platforms include genome editing, in vitro rapid amplification of immune and stem cells, a rapid in vitro evaluation system for cellular drugs, and a non-viral transfection platform. MedGenCell serves the biopharmaceutical market, collaborating with hospitals and research institutions. In early 2025, the company secured a strategic investment from a venture capital fund under the state-owned Beijing Zhongguancun Capital, which valued the company at RMB 600 million pre-investment. According to its website, the company's chairman is Deng Tao and the general manager is Yu Kun.

Keywords: cell therapy, gene editing, CRISPR, T-cell therapy, oncology, biopharmaceutical, clinical trials, non-small cell lung cancer, GMP manufacturing, PD-1 knockout, stem cells, immunotherapy, molecular biology, biotechnology, Chengdu, MedGenCell, cellular drugs, genetic engineering, hematological tumors, solid tumors